Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case [Seeking Alpha]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Play 16min Summary Intellia Therapeutics is pioneering in vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving blockbuster status. Despite a 65% stock drop since 2022, Intellia's advancements in Phase 3 trials and strong partnerships, like with Regeneron, make it a compelling buy opportunity. The company's innovative use of lipid nanoparticles for gene delivery and a robust pipeline position it as a leader in the CRISPR space, targeting large markets. With a cash position of $940m and multiple Phase 3 studies in play, Intellia is poised for substantial valuation growth and a possible Big Pharma acquisition. The major risks to the thesis are a safety setback or a failure to deliver on approval-worthy efficacy endpoints, but this is mitigated somewhat by the success of e.g., CRISPR Therapeutics/Vertex's very effective sickle cell disease therapy
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $54.00 price target on the stock.MarketBeat
- Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific MeetingGlobeNewswire
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Stifel Nicolaus from $80.00 to $64.00. They now have a "buy" rating on the stock.MarketBeat
- Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 6.7% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
NTLA
Earnings
- 8/8/24 - Miss
NTLA
Sec Filings
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- 7/24/24 - Form 4
- NTLA's page on the SEC website